Avacta presents promising findings to Boston conference

Shares in Avacta rose on Monday after the clinical stage biopharmaceutical company presented preclinical data showing its novel dual payload pre|CISION technology at a oncology conference in Boston.

  • Avacta Group
  • 27 October 2025 09:23:04
Avacta

Source: Sharecast

The pre|CISION platform is the first in the field to enable two distinct anti-cancer therapies to be delivered simultaneously to the tumour microenvironment through a single fibroblast activation protein (FAP)-mediated cleavage event, the company said.

This, it says, has the potential to overcome resistance and maximise tumour control.

Key preclinical findings have validated the dual payload release mechanism, while showing that dual payload compounds could treat specific FAP-selective tumour cells with maintained potency.

"Avacta is the first company to develop dual payload peptide drug conjugates, circumventing resistance mechanisms that cancer cells develop against single-drug therapies while maximising therapeutic effect through targeted combination delivery," Avacta said in a statement.

"This approach has the potential to address several critical challenges in cancer therapy."

The stock was up 1.9% at 65p by 0917 GMT, having risen as much as 5% earlier on.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.